Search Results - "Pieper, Karen"

Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease by Shah, Svati H., MD, MHS, Sun, Jie-Lena, MS, Stevens, Robert D., PhD, Bain, James R., PhD, Muehlbauer, Michael J., PhD, Pieper, Karen S., MS, Haynes, Carol, BS, Hauser, Elizabeth R., PhD, Kraus, William E., MD, Granger, Christopher B., MD, Newgard, Christopher B., PhD, Califf, Robert M., MD, Newby, L. Kristin, MD, MHS

“…Background Cardiovascular risk models remain incomplete. Small-molecule metabolites may reflect underlying disease and, as such, serve as novel biomarkers of…”
Get full text

Extent, Location, and Clinical Significance of Non–Infarct-Related Coronary Artery Disease Among Patients With ST-Elevation Myocardial Infarction by Park, Duk-Woo, Clare, Robert M, Schulte, Phillip J, Pieper, Karen S, Shaw, Linda K, Califf, Robert M, Ohman, E. Magnus, Van de Werf, Frans, Hirji, Sameer, Harrington, Robert A, Armstrong, Paul W, Granger, Christopher B, Jeong, Myung-Ho, Patel, Manesh R

“…IMPORTANCE: Little information exists about the anatomical characteristics and clinical relevance of non–infarct-related artery (IRA) disease among patients…”
Get full text

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial by MAHAFFEY, Kenneth W, WOJDYLA, Daniel M, HORROW, Jay, HARRINGTON, Robert A, WALLENTIN, Lars, CARROLL, Kevin, BECKER, Richard C, STOREY, Robert F, ANGIOLILLO, Dominick J, HELD, Claes, CANNON, Christopher P, JAMES, Stefan, PIEPER, Karen S

“…In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed a significant interaction between treatment and region…”
Get full text

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation by Bassand, Jean-Pierre, Virdone, Saverio, Goldhaber, Samuel Z, Camm, A John, Fitzmaurice, David A, Fox, Keith A A, Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Mantovani, Lorenzo G, Misselwitz, Frank, Pieper, Karen S, Turpie, Alexander G G, van Eickels, Martin, Verheugt, Freek W A, Kakkar, Ajay K

“…Atrial fibrillation is associated with increased risks of death, stroke/systemic embolism, and bleeding (incurred by antithrombotic therapy), which may occur…”
Get full text

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study by Becker, Richard C, Prof, Moliterno, David J, Prof, Jennings, Lisa K, Prof, Pieper, Karen S, MS, Pei, Jinglan, MS, Niederman, Alan, MD, Ziada, Khaled M, MD, Berman, Gail, MD, Strony, John, MD, Joseph, Diane, Mahaffey, Kenneth W, MD, Van de Werf, Frans, Prof, Veltri, Enrico, MD, Harrington, Robert A, Prof

“…Summary Background An antithrombotic drug is needed that safely reduces cardiovascular events in patients undergoing percutaneous coronary intervention (PCI)…”
Get full text

Representation of women in randomized clinical trials of cardiovascular disease prevention by Melloni, Chiara, Berger, Jeffrey S, Wang, Tracy Y, Gunes, Funda, Stebbins, Amanda, Pieper, Karen S, Dolor, Rowena J, Douglas, Pamela S, Mark, Daniel B, Newby, L Kristin

“…The 2007 American Heart Association guidelines for cardiovascular disease prevention in women drew heavily on results from randomized clinical trials; however,…”
Get full text

The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries by Farjat, Alfredo E., Virdone, Saverio, Thomas, Laine E., Kakkar, Ajay K., Pieper, Karen S., Piccini, Jonathan P.

“…Randomized controlled trials (RCTs) are considered the gold standard for estimating the effectiveness of a treatment. However, in many instances they are…”
Get full text

Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery by Domanski, Michael J, Mahaffey, Kenneth, Hasselblad, Vic, Brener, Sorin J, Smith, Peter K, Hillis, Graham, Engoren, Milo, Alexander, John H, Levy, Jerrold H, Chaitman, Bernard R, Broderick, Samuel, Mack, Michael J, Pieper, Karen S, Farkouh, Michael E

“…CONTEXT Several small studies have suggested that cardiac enzyme elevation in the 24 hours following coronary artery bypass graft (CABG) surgery is associated…”
Get full text

Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry by Bassand, Jean‐Pierre, Virdone, Saverio, Camm, A. John, Fox, Keith A. A., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Keltai, Matyas, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., Kakkar, Ajay K.

“…Aims This study aims to describe both management and prognosis of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation (AF), overall as…”
Get full text

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) by Fox, Keith A A, Dabbous, Omar H, Goldberg, Robert J, Pieper, Karen S, Eagle, Kim A, Van de Werf, Frans, Avezum, Álvaro, Goodman, Shaun G, Flather, Marcus D, Anderson, Frederick A, Granger, Christopher B

“…Objective To develop a clinical risk prediction tool for estimating the cumulative six month risk of death and death or myocardial infarction to facilitate…”
Get full text

Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry by Ageno, Walter, Haas, Sylvia, Weitz, Jeffrey I, Goldhaber, Samuel Z, Turpie, Alexander G G, Goto, Shinya, Angchaisuksiri, Pantep, Nielsen, Joern Dalsgaard, Kayani, Gloria, Pieper, Karen S, Schellong, Sebastian, Bounameaux, Henri, Mantovani, Lorenzo G, Prandoni, Paolo, Kakkar, Ajay K

“…Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), varies worldwide.  The Global…”
Get more information

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial by GOODMAN, Shaun G, CLARE, Robert, JAMES, Stefan K, KILHAMN, Jan, GABRIEL STEG, P, HARRINGTON, Robert A, WALLENTIN, Lars, PIEPER, Karen S, NICOLAU, Jose C, STOREY, Robert F, CANTOR, Warren J, MAHAFFEY, Kenneth W, ANGIOLILLO, Dominick J, HUSTED, Steen, CANNON, Christopher P

“…The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. We examined the relationship between PPI…”
Get full text

Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry by Verheugt, Freek W A, Fox, Keith A A, Virdone, Saverio, Ambrosio, Giuseppe, Gersh, Bernard J, Haas, Sylvia, Pieper, Karen S, Kayani, Gloria, Camm, A John, Parkhomenko, Alexandr, Misselwitz, Frank, Ragy, Hany, Ten Cate, Hugo, Keltai, Matyas, Kakkar, Ajay K

“…Many patients with atrial fibrillation suffer from comorbid vascular disease. The comparative efficacy and safety of different types of oral anticoagulation…”
Get full text

Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention by Mehta, Rajendra H, Starr, Aijing Z, Lopes, Renato D, Hochman, Judith S, Widimsky, Petr, Pieper, Karen S, Armstrong, Paul W, Granger, Christopher B, APEX AMI Investigators, for the

“…CONTEXT The incidence and timing of sustained ventricular tachycardia or fibrillation (VT/VF) and its impact on outcomes in patients with ST-elevation…”
Get full text

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) by Pagidipati, Neha J, Navar, Ann Marie, Pieper, Karen S, Green, Jennifer B, Bethel, M Angelyn, Armstrong, Paul W, Josse, Robert G, McGuire, Darren K, Lokhnygina, Yuliya, Cornel, Jan H, Halvorsen, Sigrun, Strandberg, Timo E, Delibasi, Tuncay, Holman, Rury R, Peterson, Eric D

“…Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which…”
Get full text

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation by Bassand, Jean-Pierre, Accetta, Gabriele, Al Mahmeed, Wael, Corbalan, Ramon, Eikelboom, John, Fitzmaurice, David A, Fox, Keith A A, Gao, Haiyan, Goldhaber, Samuel Z, Goto, Shinya, Haas, Sylvia, Kayani, Gloria, Pieper, Karen, Turpie, Alexander G G, van Eickels, Martin, Verheugt, Freek W A, Kakkar, Ajay K

“…The factors influencing three major outcomes-death, stroke/systemic embolism (SE), and major bleeding-have not been investigated in a large international…”
Get full text

Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation by Freeman, James V, Shrader, Peter, Pieper, Karen S, Allen, Larry A, Chan, Paul S, Fonarow, Gregg C, Gersh, Bernard J, Kowey, Peter R, Mahaffey, Kenneth W, Naccarelli, Gerald, Reiffel, James A, Singer, Daniel E, Go, Alan S, Hylek, Elaine M, Steinberg, Benjamin A, Peterson, Eric D, Piccini, Jonathan P

“…BACKGROUND:Studies evaluating the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outcomes have shown mixed results. In…”
Get full text

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry by Bassand, Jean-Pierre, Virdone, Saverio, Goldhaber, Samuel Z, Camm, A John, Fitzmaurice, David A, Fox, Keith A.A, Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Mantovani, Lorenzo G, Misselwitz, Frank, Pieper, Karen S, Turpie, Alexander G.G, van Eickels, Martin, Verheugt, Freek W.A, Kakkar, Ajay K

“…BACKGROUND:Atrial fibrillation is associated with increased risks of death, stroke/systemic embolism, and bleeding (incurred by antithrombotic therapy), which…”
Get full text

Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　― Insights From GARFIELD-AF by Koretsune, Yukihiro, Etoh, Takuma, Katsuda, Yousuke, Suetsugu, Tetsuro, Kumeda, Kenshi, Sakuma, Ichiro, Eshima, Kenichi, Shibuya, Mitsuhiro, Ando, Shin-ichi, Yokota, Naoto, Goto, Shinya, Pieper, Karen S., Allu, Jagan, Kakkar, Ajay K., Investigators, for the GARFIELD-AF

“…Background: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective non-interventional study of stroke…”
Get full text

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry by Cools, Frank, Johnson, Dana, Camm, Alan J., Bassand, Jean‐Pierre, Verheugt, Freek W. A., Yang, Shu, Tsiatis, Anastasios, Fitzmaurice, David A., Goldhaber, Samuel Z., Kayani, Gloria, Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Turpie, Alexander G. G., Fox, Keith A. A., Pieper, Karen S., Kakkar, Ajay K.

“…Background Oral anticoagulation (OAC) in atrial fibrillation (AF) reduces the risk of stroke/systemic embolism (SE). The impact of OAC discontinuation is less…”
Get full text